*To the Editor*:

In a recent issue of the *Journal*, Filewod and Lee eloquently demystified the prospects of vascular leakage in sepsis, highlighting novel therapeutic avenues ([@bib1]). The authors appropriately mentioned adrenomedullin (ADM) as a prominent example among approaches to harness vascular leakage ([@bib1]). Given the interdisciplinary therapeutic potential of the ADM pathway, further focused discussion is warranted.

ADM is a vasoactive peptide synthesized by endothelial and vascular smooth muscle cells, has diverse multiorgan roles, and diffuses freely between the circulation and the interstitium ([@bib2], [@bib3]). In the circulation, it exerts endothelial barrier--stabilizing effects, thereby mitigating vascular leakage, whereas in the interstitium, it modulates vascular tone, exerting vasodilatory effects ([@bib2], [@bib3]). As a biomarker, ADM improves prognostication in heart failure and chronic obstructive pulmonary disease ([@bib3], [@bib4]).

Among the currently available therapies for heart failure, sacubitril-based therapy potentiates ADM by inhibiting its degradation by neprilysin ([@bib5]). Adrecizumab is a monoclonal nonneutralizing antibody against the N terminus of ADM. Adrecizumab is bound to the blood compartment by virtue of its high molecular weight and leads to a dose-dependent increase of plasma ADM by compartmentalizing ADM in the circulation, and also potentially by increasing its translocation from the interstitium ([@bib3]). Although a study of adrecizumab in hospitalized patients with heart failure is currently being prepared ([@bib3]), a phase 2 study of adrecizumab in patients with early septic shock is already underway ([@bib6]). Indeed, harnessing vascular leakage in inflammation is no longer science fiction, but an active focus of interdisciplinary scientific investigation.
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